Physician profile
George Graham
NPI 1871021279
$3,431.16
in general payments reported to CMS, 2019-2025
25 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.48 · 2021: $324 · 2022: $655 · 2023: $263 · 2024: $882 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,439.10 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $432.89 | 2024-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $316.46 | 2021-2023 | Jeti |
| Philips North America LLC | $305.59 | 2024-2025 | (Ck4) Mcot, Ambulatory Monitoring & Diagnostics Undivided, Ecc Solutions |
| Amgen INC. | $260.73 | 2020-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $248.65 | 2021-2024 | Xarelto |
| Abiomed | $238.25 | 2022-2025 | |
| Inari Medical, INC. | $173.13 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Edwards Lifesciences Corporation | $167.45 | 2024-2025 | |
| Lantheus Medical Imaging, INC. | $144.19 | 2025 | |
| Astellas Pharma US INC | $120.25 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.27 | 2024-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $113.59 | 2024-2025 | |
| Siemens Medical Solutions USA, INC. | $112.28 | 2022 | |
| Stryker Corporation | $107.41 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $100.60 | 2025 | Lux-Dx Insertable Cardiac Monitor |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $83.72 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.33 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $70.96 | 2023-2025 | Verquvo, Winrevair |
| Angiodynamics, INC. | $69.38 | 2022 | |
| Pfizer INC. | $37.66 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $33.91 | 2025 | Wainua |
| Atricure, INC. | $33.69 | 2023 | |
| Scpharmaceuticals INC. | $32.75 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $19.43 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $17.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.